Cerus Corporation develops and supplies blood-safety technologies and pathogen-protected blood components for blood centers and hospitals. Its recurring news centers on the INTERCEPT Blood System for platelets and plasma, the U.S. INTERCEPT Blood System for Cryoprecipitation used to produce INTERCEPT Fibrinogen Complex, and the company’s red blood cell pathogen-reduction program.
Company updates commonly cover product revenue, gross margin trends, revenue guidance, government contract activity, international supply agreements, clinical studies involving pathogen-inactivated platelets, regulatory and pipeline developments, healthcare conference participation, and governance changes. Commercial disclosures often emphasize demand for INTERCEPT Fibrinogen Complex and adoption of pathogen inactivation technologies by blood establishments in the United States, Europe and other markets.
Cerus Corporation (CERS) will present clinical data for its INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan from May 31 to June 4, 2025. The presentations will highlight data on the system's applications for platelets, plasma, cryoprecipitated fibrinogen complex, and red blood cells.
Key presentations include positive results from the Phase 3 ReCePI study in red blood cells, INTERCEPT treated cold stored platelets, and effective inactivation of California encephalitis virus. The event features a Cerus-sponsored symposium focusing on INTERCEPT's impact on adverse events, platelet use, and inventory management in France, along with its safety in neonates.
Multiple oral and poster presentations will cover topics including cold-stored platelet concentrates, reduced hemoglobin use in cardiac surgery, and pathogen reduction effectiveness.
Cerus (CERS) has scheduled the release of its first quarter 2025 financial results for Thursday, May 1, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss financial performance and provide business updates.
Management will present detailed financial results and offer a general business overview and outlook during the call. A replay of the event will be accessible on Cerus' website until May 22, 2025.
Cerus (CERS) has received CE mark approval for its next-generation LED-based illumination device (INT200) for the INTERCEPT Blood System for platelets and plasma under the EU Medical Device Regulation (MDR). This approval enables Cerus to market the INT200 throughout the European Union and regions recognizing CE mark certification.
The INT200 represents a significant upgrade featuring enhanced physical design and new software interface while maintaining compatibility with existing processing sets. This approval completes the authorization of the INTERCEPT Blood System for both platelets and plasma within the EU MDR framework, following the 2023 CE mark approvals of INTERCEPT processing sets.
The CE mark represents the first regulatory approval for Cerus' next-generation illuminator, with additional regulatory submissions planned over coming years. The INT200 will serve as the foundation for geographic expansion and future growth of the INTERCEPT business.
Cerus (CERS) reported strong financial results for full-year and Q4 2024. Full-year product revenue reached $180.3 million, up 15% year-over-year, while Q4 product revenue was $50.8 million, a 9% increase. The company achieved significant financial improvements, including a 40% reduction in GAAP net loss to $20.9 million and positive non-GAAP adjusted EBITDA of $5.7 million for 2024.
Notable achievements include four consecutive quarters of positive operating cash flows, totaling $11.4 million for the year, a $55 million improvement from 2023. The INTERCEPT Fibrinogen Complex (IFC) product showed strong growth, with full-year revenue of $9.2 million, up 42% from the previous year.
The company reiterated its 2025 product revenue guidance of $194-200 million, including $12-15 million for IFC, projecting 8-11% growth from 2024.
Cerus (Nasdaq: CERS) has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management team is scheduled to present at a fireside chat on Wednesday, March 5, at 11:10 a.m. EST. The presentation will be accessible through a live webcast, with a replay available for 90 days following the event.
Cerus (Nasdaq: CERS) has scheduled the release of its fourth quarter and full-year 2024 financial results for Thursday, February 20, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET on the same day, featuring management discussions on financial results, business overview, and outlook.
Interested participants can access the webcast and presentation slides through Cerus' Investor Relations webpage at http://ir.cerus.com. While early joining is encouraged (10 minutes prior), it's not mandatory. A replay of the event will be available on the company's website approximately three hours after the call until March 6, 2025.
Cerus (CERS) reported preliminary full-year 2024 product revenue of $180.3 million, exceeding their guidance of $177-$179 million and marking a 15% increase over 2023. The growth was driven by strong performance in their INTERCEPT platelet franchise and IFC business, which grew 42% to reach $9.2 million in revenue.
For 2025, Cerus projects product revenue between $194-$200 million, representing 8-11% year-over-year growth. IFC revenue is expected to range from $12-$15 million. The company anticipates Q1 2025 product revenue growth of 10-15% compared to Q1 2024. Future initiatives include the planned LED Illuminator launch in Europe and geographic expansion efforts.
Cerus (Nasdaq: CERS) has announced its participation in two upcoming investor conferences. Management will present at the Stifel 2024 Healthcare Conference on Monday, November 18th at 4:10 PM ET, and attend the Craig-Hallum Alpha Select Conference on Tuesday, November 19th. A live webcast of the Stifel conference presentation will be available online, with a replay accessible on the company's website following the event.